4.70% (265) of these patients had familial history of cancer, 50.15% (2,118) were diagnosed with premenopausal breast cancer, 65.05% (2,773) were ER positive, 63.44% (2,704) were PR positive, and 26.99% (1,148) were HER-2 positive. This evidence concerns the gene ERBB2 and breast carcinoma.